Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer.
Yan Wang, Hangcheng Xu, Yiran Zhou, Liang Cui, Qiang Sa, Hong Cheng, Renchi Gao, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Xinxin Tan, Jing Bai, Li Wang, Xianghui Duan, Fan Yang, Jiayu Wang, Binghe Xu
Nat Commun 17(1) 11822
摘要
摘要
Bireociclib plus fulvestrant improves outcomes in hormone receptor-positive, HER2-negative advanced breast cancer, but molecular determinants of benefit and resistance remain unclear. Here we report an exploratory longitudinal circulating tumor DNA (ctDNA) analysis of the randomized phase Ⅲ BRIGHT-2 trial (ClinicalTrials.gov, NCT05077449) in female patients, profiling 596 plasma samples collected at baseline, on treatment, and at end of treatment with a 1,021-gene panel. Detectable baseline ctDNA and higher molecular tumor burden are associated with shorter progression-free survival in both arms, consistent with greater disease burden and intrinsic risk. MYC, PI3K-AKT and gBRCA/HRR alterations define adverse genomic risk, whereas PIK3CA-ESR1 status shows an exploratory treatment-informative signal. Landmark analyses link on-treatment ctDNA clearance or molecular tumor burden reduction with favorable subsequent outcomes. End-of-treatment profiling identifies candidate resistance-associated alterations after bireociclib, including FGFR1, MDM2, and MYC amplifications and MAPK pathway activation. Longitudinal ctDNA profiling may refine risk stratification, response monitoring, and resistance tracking during CDK4/6 inhibitor-based therapy.
KM 提取结果
0 个 Figure · 0 个 KM 面板